News

LINZESS was approved by the National Medical Products Administration for adults with IBS-C in China in January 2019. LINZESS is expected to be launched in China in the

GB-102, a pan-Vascular Endothelial Growth Factor (VEGF) inhibitor and potential twice-per-year therapy is targeted to reduce the need for frequent intravitreal injections in retinal diseases, including wet AMD,

The status was provided based on data from the phase II NOBILITY study in adult patients with proliferative lupus nephritis. Gazyva, in combination with standard of care (mycophenolate

The PREVENT trial is assessing the efficacy and safety of Cosentyx compared to placebo with the primary endpoint being ASAS40 at Week 16. All the secondary endpoints of

Topline data from this dose regimen trial is expected in the first half of 2020. “We are extremely grateful to the patients who volunteer to participate in our

Keytruda is Merck’s anti-PD-1 therapy, while Lenvima is the orally available kinase inhibitor discovered by Eisai. Keytruda plus Lenvima has been approved for the treatment of patients with

This study aims to confirm the predicted relative exposure and dose proportionality of PXL065. PXL065, the deuterium-stabilized R-stereoisomer of pioglitazone, targets mitochondrial pyruvate carrier (MPC) inhibition. PXL065 is

The primary endpoint is the change from baseline in the 6-minute walk test (6-MWT) at 12 months. Secondary endpoints will evaluate the efficacy of patisiran on quality of

The fast track designation is for the use of Farxiga in reducing the chances of cardiovascular (CV) death, or the worsening of heart failure, in adults with heart